A generic product cannot enter the market until the originator product’s IP has expired, but the development process can take ...

Objective: To investigate the relative bioavailability and bioequivalence, in fasting and fed conditions, of repeated doses of two omeprazole enteric-coated formulations in healthy volunteers.

Table III. Pharmacokinetic parameters for rebamipide following oral administration of granules or a tablet at a dose of 100mg in 27 healthy adult male volunteers [mean (SD)] ...

Eton Pharmaceuticals, Inc. announced positive results from its pivotal bioequivalence study of ET-600, a patented oral solution of desmopressin aimed at treating central diabetes insipidus.

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

After detailed deliberation, the committee recommended the grant of import and market of Saccharomyces boulardii CNCM-I 745 ...

Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 ...

(RTTNews) - Eton Pharmaceuticals (ETON) announced positive results from bioequivalence study of ET-600, a patented oral solution of desmopressin under development for the treatment of central ...

Eton Pharma announces positive results from bioequivalence study of ET-600 to treat central diabetes insipidus: Deer Park, Illinois Monday, March 17, 2025, 18:00 Hrs [IST] Eton Ph ...

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra, from ...

On March 13, Alkem Laboratories Ltd informed the stock exchanges that the Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center located in Taloja, Maharashtra was conducted by the ...